Gilead Raises Price Of New HCV Drug As It Issues Licenses To India-Based Generic Drugmakers

News outlets report on Gilead’s announcement that it will raise the price of its next generation of hepatitis C drug Sovaldi and its agreement to license the current drug to India-based drugmakers to sell at lower prices.

Reuters: Gilead to raise price for new hepatitis C drug above $84,000
“The next generation version of Gilead Sciences Inc’s $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive. Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month…” (Beasley, 9/12).

Reuters: Gilead signs pact with 7 firms for cheap copies of hepatitis C drug
“U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India-based drugmakers to sell cheaper versions of the $1,000-a-pill medicine in 91 developing nations including India…” (Kalra/Siddiqui, 9/15).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.